UK markets close in 2 hours 8 minutes

Laboratorios Farmaceuticos Rovi, S.A. (LABFF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
86.050.00 (0.00%)
At close: 11:47AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.60B
Enterprise value 4.65B
Trailing P/E 25.10
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.15
Price/book (mrq)7.62
Enterprise value/revenue 5.60
Enterprise value/EBITDA 18.94

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 368.40%
S&P500 52-week change 323.57%
52-week high 386.05
52-week low 350.88
50-day moving average 379.24
200-day moving average 358.94

Share statistics

Avg vol (3-month) 31
Avg vol (10-day) 3N/A
Shares outstanding 551.21M
Implied shares outstanding 653.51M
Float 819.28M
% held by insiders 160.25%
% held by institutions 118.55%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 41.41
Forward annual dividend yield 41.64%
Trailing annual dividend rate 31.10
Trailing annual dividend yield 31.28%
5-year average dividend yield 4N/A
Payout ratio 440.43%
Dividend date 3N/A
Ex-dividend date 403 Jul 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 20.53%
Operating margin (ttm)28.23%

Management effectiveness

Return on assets (ttm)16.34%
Return on equity (ttm)31.98%

Income statement

Revenue (ttm)829.51M
Revenue per share (ttm)15.34
Quarterly revenue growth (yoy)-3.10%
Gross profit (ttm)N/A
EBITDA 243.8M
Net income avi to common (ttm)170.34M
Diluted EPS (ttm)3.42
Quarterly earnings growth (yoy)-34.10%

Balance sheet

Total cash (mrq)25.32M
Total cash per share (mrq)0.49
Total debt (mrq)65.43M
Total debt/equity (mrq)12.04%
Current ratio (mrq)2.55
Book value per share (mrq)10.41

Cash flow statement

Operating cash flow (ttm)113.25M
Levered free cash flow (ttm)25.34M